Please sign in to follow a disease.
Appendiceal neoplasm
MONDO:0001236A benign or malignant neoplasm involving the appendix.
Also known as: appendix neoplasm, appendix tumor, appendix tumour, neoplasm of appendix, neoplasm of the appendix, neoplasm of vermiform appendix, tumor of appendix, tumor of the appendix
1523 clinical trials for this condition and its sub-types, 30 tagged with Appendiceal neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Appendiceal neoplasm
-
Appendix cancer 19 trials · 52 incl. sub-types
2 sub-types
- Appendix carcinoma 11 trials · 42 incl. sub-types Sub-types →
- Appendix lymphoma 0 trials
-
Epithelial tumor of the appendix 0 trials · 42 incl. sub-types
3 sub-types
- Appendix carcinoma 11 trials · 42 incl. sub-types Sub-types →
- Neuroendocrine tumor of the appendix, well differentiated, low or intermediate grade 0 trials · 2 incl. sub-types Sub-types →
- Appendix adenoma 0 trials Sub-types →
-
Appendix neuroendocrine neoplasm 0 trials · 2 incl. sub-types
1 sub-type
- Neuroendocrine tumor of the appendix, well differentiated, low or intermediate grade 0 trials · 2 incl. sub-types Sub-types →
-
Benign neoplasm of appendix 0 trials
1 sub-type
- Appendix leiomyoma 0 trials
Most studied deeper sub-types
-
New drug candidate CBX-12 tested in patients with Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…
Phase 1/2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug cocktail aims to make inoperable abdominal cancers operable
Disease control CompletedThis phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Smart dosing keeps chemo on track for GI cancer patients
Disease control CompletedThis study tested a doctor-designed dose adjustment algorithm to prevent unplanned delays in FOLFOX chemotherapy for people with cancers of the colon, stomach, esophagus, and other digestive organs. 52 adults participated, and the goal was to see if the algorithm could keep treat…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can acupuncture and ice chips beat chemo nerve damage?
Symptom relief CompletedThis phase 2 trial looked at whether adding acupuncture and acupressure to oral cryotherapy (sucking on ice chips) can reduce nerve pain caused by oxaliplatin chemotherapy in people with gastrointestinal cancers. 78 patients were split into two groups: one got cryotherapy alone, …
Phase 2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC